Rachel McMinn

Rachel McMinn (chief executive) discloses dealings in 2 companies, chiefly Neurogene Inc. and Intercept Pharmaceuticals, Inc. Between 4 January 2016 and 22 September 2026, the trades on record add up to 8 filings.

On the open market, the record shows 1 purchase worth €926k and 3 sales worth €139k. Netting one side against the other leaves €786k of net buying. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 3 share grants and 1 option exercise. 2026 to date brings no purchases and 1 sale.

Most recently, on 2 October 2026, the filings show an option exercise worth €17k in Neurogene Inc. The latest purchase dates back some time: it was published 698 days ago, on 25 November 2024. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.